FOLLOW US

In a fiery Florida courtroom showdown, CVS, Walgreens, and Walmart spent Wednesday dismantling the foundation of an expert’s $1.5 billion damages estimate in a sprawling opioid liability suit filed by two dozen Florida hospitals. The hospitals accuse the pharmacy giants of turning a blind eye to suspicious opioid prescriptions, a failure they say fueled addiction and left medical institutions footing the bill for the crisis.

The high-stakes trial, which began September 22, sees 26 hospitals across 15 Florida counties, including Tampa General Hospital, demanding financial accountability from the nation’s largest pharmacy chains.

At the heart of the dispute lies the testimony of economist Joseph Mason, the plaintiffs’ damages expert, whose two models estimate the hospitals’ uncompensated treatment costs between $528 million and $1.49 billion.

Defense Attacks the $1.5B Estimate

Defense lawyers came out swinging. Brian Swanson of Bartlit Beck LLP, representing Walgreens, pressed Mason on his reliance on hospital “chargemaster” data — the internal list of sticker prices hospitals use before applying discounts and insurance adjustments.

Swanson pointed out that chargemaster rates rarely reflect real payments, using a vivid example: a patient’s $155,299 listed charge for a traumatic injury was ultimately billed at only $20,027.

Similarly, Tara Fumerton of Jones Day, representing Walmart, hammered Mason over the validity of basing damages on what she called inflated theoretical prices.

“I view the chargemaster as akin to the economic cost of providing a service,” Mason countered. “It reflects the resources and effort hospitals must commit to care for opioid-harmed patients — a moral and public health obligation that carries real economic weight.”

Economic Models Under Scrutiny

Mason defended his approach, saying it attempts to measure the true economic harm inflicted on hospitals that treated patients suffering from opioid-related conditions, many of whom were uninsured or underinsured.

But Swanson pushed back, highlighting that Mason’s models do not account for critical variables — including the number of prescriptions written, or whether hospitalizations were caused by heroin, fentanyl, or legally prescribed opioids.

The defense teams implied that by excluding these nuances, Mason’s numbers exaggerated the scale of pharmacy responsibility.

Hospitals Seek Accountability Amid National Crisis

The hospitals — represented by Warren Burns, Darren Nicholson, and colleagues at Burns Charest LLP — argue that CVS, Walgreens, and Walmart failed in their duty of due diligence, routinely filling suspect prescriptions and ignoring red flags in pursuit of profit.

They claim this negligence forced hospitals to absorb the staggering costs of treating overdoses, addiction-related complications, and long-term recovery care.

Mason’s testimony painted a grim picture: “Hospitals didn’t just lose money — they bore the human and economic burden of a public health catastrophe.”

Legal Titans in the Fight

Representing Walgreens are attorneys from Bartlit Beck LLP and Hilgers Graben PLLC, while Walmart is defended by Jones Day and Markus/Moss PLLC. CVS is backed by a powerhouse team from Zuckerman Spaeder LLP, including Eric Delinsky and Marcos Hasbun.

As the trial continues, the courtroom drama underscores the mounting tension between public accountability and corporate defense, with billions of dollars — and moral responsibility — hanging in the balance.

This Pharmacies $1.5B Opioid Suit could become one of the most consequential legal battles yet in the ongoing reckoning over America’s opioid epidemic.